
|Articles|September 1, 2003
- Volume 0 0
FDA Considers Posting Names of Unapproved Drugs
Advertisement
Concern over medication mix-ups due to ?sound-alike? drugs is causing the FDA to reconsider its longstanding opposition to public disclosure of the names of drugs still in the research and development pipeline. According to officials at the FDA?s medication error prevention branch, the agency may soon propose new procedures for placing the names of unapproved drugs on the Internet?a move that some say could reduce confusion with other products and therefore lower the potential risk of medication mix-ups for patients.
Articles in this issue
almost 23 years ago
Warning: West Nile Risk Higher for Seniorsalmost 23 years ago
Seniors Accentuate the Positivealmost 23 years ago
Seniors Accentuate the Positivealmost 23 years ago
Free Directory for Seniorsalmost 23 years ago
Mind Games Fuel the Mindalmost 23 years ago
Breast-Feeding Reduces Harm of Smoking in Pregnancyalmost 23 years ago
Race Factors into Breast Cancer Treatmentalmost 23 years ago
Females Are the Tougher Sexalmost 23 years ago
Assisted Reproduction and Miscarriage Ratealmost 23 years ago
Cocaine Addiction Therapy Reduces HIV RiskAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADA 2026: Survodutide Cuts Visceral Fat and Normalizes Liver Fat in MASLD. Here's What the Data Mean for Metabolic Risk
2
The Hidden Reimbursement Crisis in Medicare’s Drug Price Negotiation Program
3
ADA 2026: Optimized Inhaled Insulin Dosing Outperforms Subcutaneous Analogs for Postprandial Glucose in T1D
4
FDA Grants Breakthrough Therapy Designation to Investigational Cannabis-Derived Therapy for Chronic Low Back Pain
5






































































































































